The fate of FTC v. Actavis, Inc. in the biosimilar context - does and should the FTC v. Actavis decision apply to reverse patent settlements between brand drug and biosimilar manufacturers?
Ho, N. G.
(2022).
The fate of FTC v. Actavis, Inc. in the biosimilar context - does and should the FTC v. Actavis decision apply to reverse patent settlements between brand drug and biosimilar manufacturers?
Biotechnology Law Report,
41(4), 194 - 199.
https://doi.org/10.1089/blr.2022.29274.nho
| Item Type | Article |
|---|---|
| Copyright holders | © 2022 Mary Ann Liebert, Inc. |
| Departments | LSE |
| DOI | 10.1089/blr.2022.29274.nho |
| Date Deposited | 13 Sep 2022 |
| URI | https://researchonline.lse.ac.uk/id/eprint/116601 |
Explore Further
- https://www.scopus.com/pages/publications/85136392716 (Scopus publication)
- https://home.liebertpub.com/publications/biotechno... (Official URL)